熱門資訊> 正文
Vigil Neuroscience在主导资产的中期研究中失败
2025-06-04 19:26
- Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
- The Watertown, Massachusetts-based biotech, which recently agreed to be acquired by Sanofi (SNY), said that based on the results, the company has decided to discontinue a Phase 2 long-term extension study for iluzanebart, also known as VGL101.
- While the experimental therapy failed to achieve beneficial effects on biomarker or clinical efficacy endpoints in the open-label trial named IGNITE, Vigil (NASDAQ:VIGL) said that the drug at 20 mg/kg and 40 mg/kg doses indicated a favorable safety, tolerability, and pharmacokinetic profile.
- Sanofi’s (GCVRZ) $470M deal in May to acquire Vigil (NASDAQ:VIGL) didn’t include iluzanebart.
More on Vigil Neuroscience
- Key deals this week: Foxconn, Sanofi, Honeywell, Adriatic Metals, Informatica and more
- Sanofi to buy Vigil Neuroscience in $470M deal (update)
- Seeking Alpha’s Quant Rating on Vigil Neuroscience
- Historical earnings data for Vigil Neuroscience
- Financial information for Vigil Neuroscience
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
